A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
Metastatic Breast Cancer
Conditions: official terms
Breast Neoplasms
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Capecitabine Type: Drug
Name: Etoposide Type: Drug
Overall Status
This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- female patients between 18 and 65 years old

- patients with metastatic breast cancer previousely treated with A/T

- able and willing to give consent to participate in the study

Exclusion Criteria:

- pregnant or lactating females

- other tumor history

- instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection

- concurrent disease or condition that would make the patient inappropriate for study participation

- resist to participate in the study
Peking University Cancer Hospital & Institute
Beijing, Beijing, China
Status: Recruiting
Contact: Yan Wei, Doctor - 0086-10-88196012 - beizhongwy@163.com
Start Date
January 2013
Completion Date
December 2016
Peking University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page